Drug-Induced Pulmonary Arterial Hypertension: a Review.
Publication/Presentation Date
4-18-2017
Abstract
Pulmonary arterial hypertension (PAH) is a subgroup of PH patients characterized hemodynamically by the presence of pre-capillary PH, defined by a pulmonary artery wedge pressure (PAWP) ≤15 mmHg and a PVR >3 Wood units (WU) in the absence of other causes of pre-capillary PH. According to the current classification, PAH can be associated with exposure to certain drugs or toxins such as anorectic agents, amphetamines, or selective serotonin reuptake inhibitors. With the improvement in awareness and recognition of the drug-induced PAH, it allowed the identification of additional drugs associated with an increased risk for the development of PAH. The supposed mechanism is an increase in the serotonin levels or activation of serotonin receptors that has been demonstrated to act as a growth factor for the pulmonary artery smooth muscle cells and cause progressive obliteration of the pulmonary vasculature. PAH remains a rare complication of several drugs, suggesting possible individual susceptibility, and further studies are needed to identify patients at risk of drug-induced PAH.
Volume
22
Issue
3
First Page
289
Last Page
297
ISSN
1573-7322
Published In/Presented At
Garg, L., Akbar, G., Agrawal, S., Agarwal, M., Khaddour, L., Handa, R., & ... Dalal, B. D. (2017). Drug-induced pulmonary arterial hypertension: a review. Heart Failure Reviews,22(3), 289-297. doi:10.1007/s10741-017-9612-9
Disciplines
Cardiology | Medical Sciences | Medicine and Health Sciences
PubMedID
28417295
Department(s)
Department of Medicine, Cardiology Division, Department of Medicine Fellows and Residents
Document Type
Article